RAMM Pharma

RAMM Pharma EPS Growth

The EPS Growth of RAMM Pharma (RAMM.CN) as of Nov 5, 2026 is 46.01 %. In the previous year, EPS Growth was -113.73 % — a change of -140.45% (higher).

EPS Growth

46.01 %

YoY

-140.45%

Last updated:

EPS Growth of RAMM Pharma is 2025 46.01 % . EPS Growth of RAMM Pharma was 2024 -113.73 % . It decreases by -140.45% higher compared to the previous year.

The RAMM Pharma EPS Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS Growth
Date
EPS Growth
Jan 1, 2019
-896.29 CAD
Jan 1, 2020
-10.04 CAD
Jan 1, 2021
22.74 CAD
Jan 1, 2022
-197.46 CAD
Jan 1, 2023
62.23 CAD
Jan 1, 2024
-113.73 CAD
Jan 1, 2025
46.01 CAD
The RAMM Pharma EPS Growth history
YEAREPS GrowthYoY
46.01 %-140.45%
-113.73 %-282.75%
62.23 %-131.52%
-197.46 %-968.33%
22.74 %-326.53%
-10.04 %-98.88%
-896.29 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RAMM Pharma Stock analysis

What does RAMM Pharma do? RAMM Pharma Corp generates revenue through cannabinoid pharmaceuticals and cannabis-based products, with brands like NettaLife, NettaPet, NettaPet Senior, NettaPet Puppies, and NettaVet targeting pet owners and veterinary markets. The company also sells cosmetics under the Cannabipiel line, including Cannabipiel Nite, Cannabipiel Body Lotion, and Cannabipiel Shampoo, catering to consumers seeking cannabinoid-infused skincare and personal care solutions. Subsidiaries such as Canapar Corp. and Medic Plast SA support production and commercialization across pharmaceutical specialties, household products, and food sectors. The firm’s product portfolio spans pharmaceuticals, pet care, cosmetics, and household items, with NettaPet and NettaVet focusing on animal health and Cannabipiel products targeting human skincare. Revenue streams include direct sales of branded items like Cannabipiel Tite and Cannabipiel Cleaning Emulsion to retail and specialty markets, while subsidiaries handle manufacturing and export operations for global distribution. Brands like Glediser SA and Yurelan SA contribute to the commercialization of diverse product categories under the company’s umbrella. RAMM Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RAMM Pharma stock

EPS Growth of RAMM Pharma is 46.01 % in 2025.

On Eulerpool you can find the complete historical development of EPS Growth RAMM Pharma since 2006 – with annual values, charts, and detailed analysis.

EPS growth measures the percentage change in earnings per share. It accounts for both profit changes and share count changes.

To evaluate EPS Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS Growth.

EPS Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS Growth's RAMM Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — RAMM Pharma

All Key Metrics — RAMM Pharma